A Chinese-made vaccine for coronavirus has entered the final stage of testing in Brazil. The vaccine, developed by private Chinese pharmaceutical firm Sinovac Biotech entered the final phase after volunteers received the first doses of the drug. It became the third in the world to enter Phase 3 clinical trials, or large-scale testing on humans — the last step before regulatory approval.
Around 9,000 health workers across six Brazilian states will receive the vaccine, known as CoronaVac, in two doses over the next three months under the study.
Sinovac is partnering with a Brazilian public health research center, the Butantan Institute, on the trials. If the vaccine proves safe and effective, the institute will have the right to produce 120 million doses under the deal, according to officials.
Brazil is also helping carry out Phase 3 testing of another experimental vaccine, developed by Oxford University and pharmaceutical firm AstraZeneca.
Studies published Monday in British medical journal The Lancet found two vaccine candidates were safe and produced an immune response in Phase 2 trials: the Oxford vaccine and another Chinese-made vaccine, developed by pharmaceutical firm CanSino Biologics and the Beijing Institute of Biotechnology.
Source: The News